Cascade of Costs Could Push New Gene Therapy Above $1 Million Per Patient

Kaiser Health News – Outrage over the high cost of cancer care has focused on skyrocketing drug prices, including the $475,000 price tag for the country’s first gene therapy, Novartis’ Kymriah, a leukemia treatment approved in August.

But the total costs of Kymriah and the 21 similar drugs in development — known as CAR T-cell therapies — will be far higher than many have imagined, reaching $1 million or more per patient, according to leading cancer experts. The next CAR T-cell drug could be approved as soon as November.

Read more at Kaiser Health News.

News Image
gene therapy
Action
Industry
Image Citation

yourgenomeCC BY-NC-SA 2.0